StillCanna Signs C$6 Million Per Month Agreement with California Based BioScience Enterprises, Inc. to Supply CBD

Vancouver, British Columbia–(Newsfile Corp. – March 28, 2019) – STILLCANNA INC. (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce that the Company has entered into a binding letter of intent with BioScience Enterprises, Inc. of California (“BioScience”) to supply C$6,000,000 of CBD isolate per month for an initial term of 6 months, such term may be extended by mutual agreement of the parties.

The Company anticipates that, subject to applicable stock exchange and regulatory approval, it will enter into a definitive agreement (the “Definitive Agreement”) with BioScience within the 60-day due diligence period under the binding letter of intent.

The Company expects to begin delivering on its contract in August of 2019 utilizing its Polish harvest of 1,500 hectares of hemp.

“We have visited BioScience Enterprises facilities,” stated Jason Dussault CEO of StillCanna. “We are impressed with their industry knowledge and capabilities. We are pleased to be a supplier of CBD isolate and hope to establish a long-standing relationship with BioScience. We believe this strategic arrangement compliments our business model and will help us reach our corporate milestones.”

Richard Parker, President of Operations, BioScience Enterprises, Inc. mentioned: “We are thrilled to be working with an innovative group like StillCanna on a partnership. Having a high standard for quality product is what makes BioScience a reputable supplier, without producers like StillCanna that wouldn’t be possible.”

ABOUT BIOSCIENCE ENTERPRISES, INC.

Since its inception in 2018 – Bioscience has emerged as a leading contract manufacturer and supplier of CBD nationwide. The company native to California has contracts across the continental USA and Canada for the supply of EU and domestic high-grade isolate, distillate and a variant of finished products. The company is housed in a secure 18,000 square foot plant, which is capable of a monthly output of 1.5 million glass tinctures, 2 million vape PET products, 1.5 million cartridges and 1.5 million disposable pens. BioScience supplies for many of America’s known brands and supplies bulk CBD to various industry manufacturing companies. The company intends to apply through the United States DEA for their own license to import hemp-derived CBD from around the world. BioScience strives to maintain its purest CBD supply on the market through a world-class quality assessment and quarantine process. BioScience currently estimates to contract over 100mm in gross sales through 2019.

For more information, please visit www.bioscience-enterprises.com

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.StillCanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna is anticipated to be one of the largest processors and providers of market-ready CBD in Europe.

For more information, please visit www.StillCanna.com

On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: accounting@jclpartners.ca

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the expectation of the Company entering into the Definitive Agreement by the expiry of the due diligence period and the terms of the Definitive Agreement are expected to reflect the binding letter of intent as anticipated by management. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enter into the Definitive Agreement by the expiry of the due diligence period and that the Definitive Agreement will reflect the terms of the binding letter of intent as anticipated by management. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enter into the Definitive Agreement by the expiry of the due diligence period, that the LOI will be terminated and that the anticipated CBD purchase will not be completed and that the Company may not supply CBD isolate to BioScience on the terms as anticipated by management. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Signs Definitive Agreement for the Acquisition of a Leading European Hemp Cultivator Olimax

March 18, 2019 – Vancouver, British Columbia – StillCanna Inc. (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce that today, March 18th, 2019, the Company signed of a definitive agreement to complete the acquisition of Olimax NT SP. Z .O.O (“Olimax”), a fully-licensed, privately-owned, vertically-integrated cultivator and producer of cannabidiol (“CBD”) in Poland, for total consideration consisting of 24 million common shares of StillCanna at a deemed per share price of C$1.15 and a cash payment of C$2 million (the “Olimax Transaction”).

StillCanna, a European-focused CBD producer with operations in Romania will acquire Olimax as a means to further its strategy of providing large quantities of high-quality CBD extracts to the European and global markets. The Olimax Transaction provides StillCanna with a vertically-integrated and licensed cultivator, extractor and formulator of CBD. Olimax’s core strength is in agriculture, with over 20-years of experience in farming hemp, in addition to having a fully-developed product line and a proprietary, European Union (“EU”) certified, high-CBD content hemp varietal. Olimax successfully cultivated and harvested hemp from over 600 hectares in 2018.

Jason Dussault, Chief Executive Officer of StillCanna commented, “It is rare when the core competencies of two companies complement each other so well. Olimax’s agricultural experience matched with our extraction expertise creates the perfect storm. The combined company will have the capacity to produce 16 million grams of high-potency CBD for the European and global market in 2019.  We estimate that with a further investment of C$10 million for land lease, planting and harvesting we expect to expand to over 60 million grams by 2021.”

TRANSACTION RATIONALE

  • The transaction bolsters StillCanna’s pro-forma production profile to 16 million grams of CBD in 2019, with potential to grow to 32 million grams in 2020 and over 60 million grams in 2021.
  • The addition of Olimax’s two founders, with their extensive 20-year history and academic background, provides StillCanna with significant internal cultivation expertise.
  • Improves alignment of management as Olimax’s founders would hold 29% of the pro-forma company (20 million shares subject to a 36-month escrow).

TERMS OF THE TRANSACTION

Under the terms of the Olimax Transaction, StillCanna will acquire all the issued and outstanding shares of Olimax from the arm’s length shareholders of Olimax for total consideration consisting of 24 million common shares of StillCanna and a cash payment of C$2.0 million. Following the acquisition, Olimax will become a wholly-owned subsidiary of StillCanna. Subject to completion of the Olimax Transaction and the Brokered Financing, StillCanna plans to invest up to C$12.0 million to expand Olimax’s capacity in agriculture, associated infrastructure, and working capital. Additionally, StillCanna has secured the services of the Olimax founders for a period of a minimum of three years to aid with the anticipated expansion of the business in Poland and throughout the EU. The Olimax Transaction is subject to customary conditions, including regulatory and exchange approval, due diligence, and StillCanna closing the Brokered Financing. The Olimax Transaction is expected to close shortly after satisfaction of all outstanding conditions under the Definitive Agreement, which closing date is expected to occur in the second quarter of 2019.

PRIVATE PLACEMENT FINANCING

StillCanna is also pleased to announce that it has entered into an  agreement with Canaccord Genuity Corp. (the “Agent”) to raise, on a commercially reasonable efforts private placement basis up to 17,400,000 subscription receipts (the “Subscription Receipts”) at a price of C$1.15 per Subscription Receipt (the “Issue Price”) for aggregate gross proceeds of up to C$20,010,000 (the “Brokered Financing”). In addition, the Company has granted the Agent an option to increase the size of the Brokered Financing by up to 4,350,000 Subscription Receipts for additional gross proceeds of C$5,002,500, exercisable in whole or in part at any time prior to the closing of the Brokered Financing, for aggregate gross proceeds of up to C$25,012,500.

Each Subscription Receipt shall entitle the holder thereof to receive, upon satisfaction of certain escrow release conditions (including the completion of the Olimax Transaction) and without payment of any additional consideration or any further action on the part of each holder thereof, one unit of StillCanna (a “Unit”). Each Unit will consist of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).  Each Warrant will be exercisable to acquire one Common Share for a period of 12-months from the date the escrow release conditions are satisfied at an exercise price of C$1.73. If the escrow release conditions are not satisfied by June 30, 2019, the Subscription Receipts will be canceled and all proceeds from the Brokered Financing will be returned to subscribers.

The Company intends to use the net proceeds of the Brokered Financing to expand CBD processing capacity at the Company’s facility in Romania, to build out Olimax’s CBD extraction facility and agricultural capabilities, along with working capital and general corporate expenditures.

The Agent will be paid a cash commission equal to 7.0% of the gross proceeds of the Brokered Financing and will also receive warrants (the “Compensation Warrants”) to acquire that number of Units which is equal to 7.0% of the aggregate number of Subscription Receipts sold under the Brokered Financing. Each Compensation Warrant will be exercisable at the Issue Price for a period of 12-months following the date the Escrow Release Conditions are satisfied.

The Brokered Financing is expected to be completed on April 11th, 2019 (the “Closing Date”), or such other date as mutually agreed to by the Company and the Agent, subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued pursuant to the Brokered Financing will be subject to a four month and one day hold period from the Closing Date, in accordance with applicable Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”) or any state securities laws and may not be offered or sold in the United States or to or for the account or benefit of US persons unless registered under the US Securities Act and applicable state securities laws or an pursuant to an exemption from such registration as available.

For more information, please visit www.StillCanna.com

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com
Phone: 778-838-3692

ABOUT OLIMAX

Olimax is a fully integrated and licensed cultivator, extractor and formulator of CBD in Poland with operations spanning over 20 years. Having recently successfully cultivated and harvested over 600 hectares of hemp, they intend to expand their agricultural footprint to over 5,000 hectares by 2021. Olimax has registered a high-potency CBD hemp varietal with the EU and holds rights to proprietary harvesting and processing equipment and techniques. In addition to being experienced in agriculture, Olimax has also formulated a large number of CBD and hemp-based products which span from CBD oils and hemp protein to cosmetics and beverages.  Through significant experience and industry connections, Olimax has established itself as a leader in hemp cultivation and processing throughout Europe. The company has more recently focused on cultivating an extensive bank of seeds from their proprietary and registered Glyana strain.  This seed bank gives the company the freedom to significantly and independently expand its cultivation holdings.  Olimax’s founders have over 20 years of experience in growing and formulating CBD products, are widely considered agricultural experts in their field and hold degrees in chemistry and physics.  The combination of education, practical experience and a true passion for the hemp plant has propelled them to be true leaders in their field and widely respected throughout the European hemp industry.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe.  Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax Transaction, StillCanna will be one of the leading processors and providers of market-ready CBD in Europe.

StillCanna’s Anchor Extraction Customer Increases Its Monthly Order By Over 300%

VANCOUVER, British Columbia, STILLCANNA INC. (FORMERLY EVI GLOBAL GROUP DEVELOPMENTS CORP.) (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce the Company’s joint venture partner and anchor customer, UK based Dragonfly BioSciences, LLC, has increased its minimum monthly order of 50 kilos of CBD per month to over 170 kilos per month for the next quarter.

“This increase in extraction volume from Dragonfly is a testament to their success, our business timing and the demand for CBD in Europe,” suggested Jason Dussault, CEO of StillCanna. “Dragonfly’s minimum contract for 50 kilos a month made our Romanian extraction facility cash flow positive and profitable. This new order accelerates the Company’s goal of meeting its 2019 revenue targets. Once again, I would like to thank our team for doing an amazing job!”

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company, based in Vancouver, British Columbia, that is focused on large scale CBD extraction in Europe. The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a UK based supplier of CBD. The Company continues to look for other industry acquisitions that will enhance shareholder value.

For further information please contact:
Joel Leonard, CFO, Director, StillCanna Inc.
E-mail: joel@stillcanna.com
Telephone: (778) 838-3692

Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

EVI Global Group Developments Corp. (CSE: EVI) Changes to StillCanna Inc. (CSE: STIL), a Leading Extractor of CBD in Europe, and Begins Resumption of Trading

VANCOUVER, British Columbia, STILLCANNA INC. (FORMERLY EVI GLOBAL GROUP DEVELOPMENTS CORP.) (CSE: STIL) (“StillCanna” or the “Company”) is pleased to announce the Company has completed a change of business from a mining issuer to a life sciences issuer. The Company received approval from its shareholders for the Change of Business and has received approval from the Canadian Securities Exchange (the “CSE“) to resume trading. StillCanna intends to be a leading extractor of CBD in Europe in 2019.

In connection with the Change of Business, the Company also announces that, effective March 15, 2019, it has changed its name from “EVI Global Group Developments Corp.” to “StillCanna Inc.” Trading of the Company’s common shares will resume under the new name and under the new ticker symbol “STIL” as of market open March 15, 2019. The new CUSIP will be 86071P107 and the new ISIN number will be CA86071P1071.

The Company is also pleased to announce it has closed its previously announced Definitive Share Exchange Agreement with Borganic Consulting Inc. (“Borganic“) dated October 15, 2018, in which the Company acquired all the issued and outstanding shares of Borganic, being 13,098 common shares, in exchange for 15,000,000 common shares of the Company (the “Transaction“). Following the closing of the Transaction, the Company had 57,943,000 common shares of the Company issued and outstanding.

Upon closing of the Transaction on February 26, 2019, Shae De Jaray was appointed Chief Technical Officer of the Company and Marc Crimeni was appointed a director of the Company.

“We’ve come a long way in a short time”, pointed out Jason Dussault, CEO of StillCanna.  “Completing our first acquisition and resuming trading are great milestones for the Company. All of our required extraction equipment is on site at our European facility. To enhance shareholder value, we continue to look at various acquisition opportunities globally.”

In connection with the Transaction, the Company also issued 1,800,000 common shares to certain finders. It also issued 2,000,000 common shares to certain consultants in exchange for financial advisory services.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a UK based supplier of CBD. The Company continues to look for other industry acquisitions that will enhance shareholder value.

For further information please contact:
Joel Leonard, CFO, Director, StillCanna Inc.
E-mail: joel@stillcanna.com
Phone: (778) 838-3692

 

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

EVI’s European Based Extraction Facility Initiates Hemp Processing

Vancouver, British Columbia–(Newsfile Corp. – February 19, 2019) – EVI GLOBAL GROUP DEVELOPMENTS CORP. (CSE: EVI) (“EVI” or the “Company) is proud to announce it has begun the initial processing of hemp in its European based extraction facility.

The first step in extraction of CBD from industrial hemp is to take the whole plant and separate the seeds, leaves, stalks and flowers prior to the CBD extraction process. Only the flowers from the hemp plant are used to extract CBD. The Company has begun the separation process, stockpiling CBD rich flower for extraction. The facility is expected to have the capability to process over 1,000,000 pounds of hemp annually.

The facility has been designed to meet EU GMP certification. It is expected to have the capability of extracting up to 3,000 pounds of flower daily, making it the largest processor of finished market ready CBD molecules in Europe.

“As the global cannabis business matures through 2019 the necessity for efficient, scalable and professional cannabis extraction has become abundantly clear. Companies that can rise to the highest standards of extraction will likely have an advantage in 2019 and beyond,” commented Jason Dussault, CEO of EVI.

“Almost weekly, one of our esteemed industry colleagues announces they’re breaking ground on a large extraction facility that is still 12 to 18 months out. Our founders have been extracting cannabinoids for over five years and their knowledge and vision has given us first mover advantage in Europe.”

“Our engineering staff’s attention to detail, operating procedures, customized equipment and implementation has resulted in a unique extraction facility that is deploying an efficient extraction system unlike any other facility. I couldn’t be more proud of our team.”

As the Company completes the final steps of equipment placement and testing, it is expected to continue to process its hemp inventory in preparation for extraction.

For pictures, videos and more updates please visit The Stillcanna Report at www.thestillcannareport.com

For further information please contact: Jason Dussault, CEO, Director, EVI Global Group Developments Corp. E-mail: jason@stillcanna.com

EVI Global firms up acquisition of Borganic Consulting

EVI ANNOUNCES PROPOSED ACQUISITION OF BORGANIC CONSULTING INC.

In connection with the letter of intent with Borganic Consulting Inc. previously announced on Sept. 6, 2018, EVI Global Group Developments Corp. has entered into a definitive share exchange agreement with Borganic under which the company has agreed to acquire all the issued and outstanding shares of Borganic in exchange for an aggregate of 30 million common shares of the company, being 43.57 per cent of the company’s total issued and outstanding shares. The share exchange agreement remains subject to a number of conditions, including but not limited to the approval of the Canadian Securities Exchange, receipt of all other required regulatory approvals and customary closing conditions.

The company is also pleased to announce 1.05 million stock options have been granted to certain consultants pursuant to the company’s stock option plan. The options are immediately exercisable for a period of five years at a price of 63 cents per share.

The company is also proposing a change of business from a mining issuer to a life sciences issuer.

Completion of the change of business is subject to a number of conditions, including Canadian Securities Exchange and shareholder approval.

“I believe 2019 will be known as the year of CBD,” explained EVI’s chief executive officer, Jason Dussault. “In all businesses, timing is everything. We are at the right place, at the right time, with the right team. I feel our agreements and technologies position us perfectly in this marketplace. I see a future that is salt, pepper, CBD!”

About Borganic Consulting Inc.

Borganic is focused on the commercial extraction of cannabidiol from industrial hemp and has engineered a proprietary commercial-scale extraction process that is more cost-efficient than other traditional extraction processes. Borganic’s technology utilizes a food-grade ethanol extraction method that is far cleaner than many of the other commercial operations which use harmful and potentially carcinogenetic products such as hexane and butane for extraction.

About EVI Developments Corp.

EVI Global Group Developments is a natural resource company based in Vancouver, B.C., engaged in the acquisition, exploration and development of mineral properties, with its primary focus on its silica properties, located within British Columbia.

We seek Safe Harbor.

 

EVI Global Group closes $4-million private placement

EVI ANNOUNCES CLOSING OF OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT

EVI Global Group Developments Corp. has closed its non-brokered private placement previously announced on Sept. 5, 2018. Due to increased demand, the previously announced private placement was increased from $3-million to $4-million with 16 million units at a price of 25 cents per unit.

Each unit in the private placement comprises one common share and one-half of a transferable common share purchase warrant. Each whole warrant is exercisable into one additional common share at a price of 50 cents for a period of one year. The securities will be subject to a four-month-and-one-day hold period under applicable securities laws.

In connection with the private placement, EVI Global Group Developments paid certain arm’s-length finders a finder’s fee consisting of: (i) cash equal to 6 per cent of the total gross proceeds from subscribers introduced to EVI Global Group Developments by the applicable finder; and (ii) such number of finders’ warrants equal to 6 per cent of the total number of shares issued to subscribers introduced to EVI Global Group Developments by the applicable finder. Each finder’s warrant is exercisable into one additional common share at a price of 50 cents for a period of one year.

EVI Global Group Developments intends to use the net proceeds from the private placement for expenditures related to previously announced letter of intent with Borganic Consulting Inc., general working capital and other corporate matters.

 

EVI Global Group to acquire Borganic Consulting

EVI GLOBAL GROUP DEVELOPMENTS CORP. ANNOUNCES THE SIGNING OF A NON-BINDING LETTER OF INTENT WITH BORGANIC CONSULTING INC. AND NON-BROKERED PRIVATE PLACEMENT OF UNITS

EVI Global Group Developments Corp. has signed a non-binding letter of intent with Borganic Consulting Inc., which is focused on the commercial extraction of cannabidiol (CBD) from industrial hemp. Borganic has engineered a proprietary commercial-scale extraction technology that is more cost-efficient than other traditional extraction processes. Borganic has also secured an exclusive joint venture partnership with United Kingdom-based DragonFly Biosciences LLC to build a CBD extraction facility to service the European Union (EU). DragonFly’s 2018 harvest of 420 hectares of CBD-rich hemp is expected to produce a minimum of 4.5 million grams of CBD. The extraction facility has the capability to produce over 18 million grams of CBD annually, making it one of the largest refineries of CBD in Europe. The company has also received multiple enquiries from other European Union-based hemp producers to extract CBD for them under contract. Cannabis News Wire projects that the worldwide CBD market will grow to more than a $2-billion industry within two years with a 39-per-cent compounded annual growth rate.

The letter of intent is for EVI to acquire all the issued and outstanding shares of Borganic for a purchase price consisting of 30 million shares of EVI, adjusted for any of Borganic’s outstanding liabilities on the closing date. As a condition to closing the acquisition, EVI will close a financing to raise an aggregate of $3-million. Borganic has granted EVI a binding 60-day exclusivity period to execute a definitive agreement, complete due diligence and raise the required capital. The acquisition is anticipated to close in Q4 2018, assuming legal, regulatory and exchange approval of the transaction.

Private placement

The company has arranged a non-brokered private placement offering of up to 12 million units at a price of 25 cents per unit for gross proceeds of up to $3-million. Management of the company may decide to increase the size of the financing by up to an additional $500,000. Each unit will consist of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder to purchase one common share of the company at a price of 50 cents for one year. The units issued in the offering are subject to a four-month hold period.

The company may pay finders’ fees in connection with the financing to certain eligible finders in the form of cash and/or securities.

“The use of CBD in the EU far exceeds its use in North America and represents mostly untapped business opportunity. Borganic’s partnership with DragonFly positions Borganic a year ahead of most competitors. This is the opportunity we’ve been looking for,” exalted Jason Dussault, chief executive officer of EVI. “The anticipated closing of this strategic acquisition is expected to establish us as a market leader in the CBD manufacturing market within the EU.”

About EVI Global Group Developments Corp.

EVI Global Group Developments is a natural resource company based in Vancouver, B.C., engaged in the acquisition, exploration and development of mineral properties, with its primary focus on its silica properties, located within British Columbia.

We seek Safe Harbor.